Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...

Galleri is a multi-cancer early detection (MCED) or 'liquid biopsy' test that Grail says can spot signs of up to 50 different ...

The Hims & Hers Multi-Cancer Test by Galleri® looks for a shared signal of 50+ types of cancer, including those without recommended screenings. In addition to recommended screenings, this simple blood ...

Grail has filed for Food and Drug Administration approval of its multi-cancer early detection test, the company said Thursday ...

Hims & Hers Health, Inc. (HIMS) came under the spotlight on Wednesday after the company unveiled a blood test to detect signals for more than 50 types of cancer, often before symptoms appear. Called ...

GRAIL, Inc. GRAL announced the submission of the final module of its premarket approval application to the FDA for the Galleri multi-cancer early detection (MCED) test. The FDA had previously granted ...

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

NHS patients will be told their real-time cancer risk with the help of gadgets such as smartwatches. Everyone will be able to access “real-time personalised insights about their cancer risk” within a ...